Parallel Group, Placebo-Controlled, Tolerability and Safety Study of Thioctic Acid and Deprenyl in HIV Dementia

The Dana Foundation5 个研究点分布在 1 个国家目标入组 32 人开始时间: 2001年8月31日最近更新: 2005年6月24日

适应症

试验速览

阶段: 2 期
状态: 已完成
发起方: The Dana Foundation
入组人数: 32
试验地点: 5

研究概览研究设计入排标准研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to see if it is safe and effective to give thioctic acid and deprenyl (selegiline hydrochloride), alone or in combination, to HIV-infected patients who have mild to moderate dementia (a decline in their mental abilities).

详细描述

Patients are randomized to receive thioctic acid alone, deprenyl alone, thioctic acid/deprenyl, or placebo alone for 10 weeks, after which all patients may receive active drug on an open-label basis. Patients must have seven clinic visits.

研究设计

研究类型: Interventional
主要目的: Treatment
盲法: Double

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

未提供

研究者

发起方

The Dana Foundation

申办方类型

Other

研究点 (5)

Loading locations...

相似试验

已完成

1 期

Single Rising Dose Study to Assess Safety, Tolerability and Pharmacokinetics of BI 661051.Healthy

NCT01343719Boehringer Ingelheim64

终止

2 期

A Study To Evaluate PF-00915275 In Subjects With Type 2 Diabetes Mellitus For 4-WeeksDiabetes Mellitus, Type 2

NCT00427401Pfizer40

终止

2 期

Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid ArthritisArthritis, Rheumatoid

NCT00634933Pfizer222

已完成

2 期

28 Day Repeat Dose in Cystic Fibrosis PatientsCystic Fibrosis

NCT00903201GlaxoSmithKline146

已完成

1 期

First In Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04427429 Administered Intravenously To Healthy Adult VolunteersHealthy Volunteers

NCT01011296Pfizer24